Autism Panel Chair's Company Ties Spark Ethics Concerns
John Gaitanis, the new chair of the federal Interagency Autism Coordinating Committee, co-founded Meadow Health, a telehealth company selling leucovorin for autism. He says he divested his financial interest before taking the role, but HHS has not confirmed. Some ethicists question the lack of evidence for leucovorin and the appearance of conflict.
Gaitanis’s appointment to lead both the IACC and NICHD places him at the center of federal autism research and policy, while his prior stake in Meadow Health—a telehealth firm marketing leucovorin to families—has drawn scrutiny. The company launched in April and emphasizes compounded, at-home prescriptions. Although Gaitanis is absent from its public-facing materials, his co-founder role and the drug’s unproven autism use raise questions about regulatory overlap.
Leucovorin’s popularity spiked after media coverage and a White House briefing, despite limited evidence. The FDA’s eventual label change narrowed approval to an ultra-rare genetic condition, not general autism. This gap between promoted use and official indication underscores tensions between commercial interests and evidence-based practice within federal health leadership.
This story could affect trust in federal autism guidance, as families may question whether committee decisions prioritize evidence or commercial ties. If conflicts are perceived as unaddressed, it may also influence how clinicians and researchers view the IACC’s credibility. Patients seeking leucovorin could face confusion about its legitimacy, while policymakers might face pressure to strengthen ethics disclosure rules for appointed health officials.